Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.39 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.39 |
| ▸ | KCNQ4 | P56696 | 1/20 | 0.39 |
| ▸ | KCNQ5 | Q9NR82 | 1/20 | 0.39 |
| ▸ | EGFR | P00533 | 4/20 | 0.39 |
| ▸ | KDR | P35968 | 4/20 | 0.39 |
| ▸ | MEN1 | O00255 | 3/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | PABPC1 | P11940 | 2/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.37 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.37 |
| ▸ | JMJD6 | Q6NYC1 | 1/20 | 0.37 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.36 |
| ▸ | AGPAT2 | O15120 | 1/20 | 0.36 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.36 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30795297 | 1.00 | RAB9A (0.39) | RAB9AKCNQ3KCNQ2KCNQ4KCNQ5 | |
| SCHEMBL2070737 | 0.84 | KDR (0.40) | RAB9AKCNQ3KCNQ2KCNQ4KCNQ5 | |
| SCHEMBL2071931 | 0.84 | KCNQ3 (0.42) | KCNQ3KCNQ2KCNQ4KCNQ5EGFR | |
| SCHEMBL30824693 | 0.84 | KCNQ3 (0.42) | KCNQ3KCNQ2KCNQ4KCNQ5EGFR | |
| SCHEMBL30794647 | 0.84 | KLKB1 (0.45) | RAB9AKCNQ3KCNQ2KCNQ4KCNQ5 | |
| SCHEMBL2072308 | 0.84 | KLKB1 (0.45) | RAB9AKCNQ3KCNQ2KCNQ4KCNQ5 | |
| SCHEMBL30795429 | 0.80 | KCNQ3 (0.47) | RAB9AKCNQ3KCNQ2KCNQ4KCNQ5 | |
| SCHEMBL2070740 | 0.80 | SMN1; SMN2 (0.53) | RAB9AKCNQ3KCNQ2KCNQ4KCNQ5 | |
| SCHEMBL2069986 | 0.80 | KCNQ3 (0.47) | RAB9AKCNQ3KCNQ2KCNQ4KCNQ5 | |
| SCHEMBL30795181 | 0.78 | KCNQ2 (0.62) | RAB9AKCNQ3KCNQ2KCNQ4KCNQ5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100256145-A1 | USE OF KCNQ POTASSIUM CHANNEL OPENERS FOR REDUCING SYMPTOMS OF OR TREATING DISORDERS OR CONDITIONS WHEREIN THE DOPAMINERGIC SYSTEM IS DISRUPTED | H. LUNDBECK A/S (DK) | 2010-10-07 | — | — | US | claimed |
| CN-101790374-A | Use of kncq potassium channel openers for reducing symptoms of or treating disorders or conditions wherein the dopaminergic system is disrupted | LUNDBECK & CO AS H | 2010-07-28 | — | — | CN | claimed |
| EP-2185149-A1 | USE OF KNCQ POTASSIUM CHANNEL OPENERS FOR REDUCING SYMPTOMS OF OR TREATING DISORDERS OR CONDITIONS WHEREIN THE DOPAMINERGIC SYSTEM IS DISRUPTED | H. Lundbeck A/S (DK) | 2010-05-19 | — | — | EP | claimed |
| WO-2009015667-A1 | USE OF KNCQ POTASSIUM CHANNEL OPENERS FOR REDUCING SYMPTOMS OF OR TREATING DISORDERS OR CONDITIONS WHEREIN THE DOPAMINERGIC SYSTEM IS DISRUPTED | H. LUNDBECK A/S (DK) | 2009-02-05 | — | — | WO | claimed |
| US-20060183791-A1 | Substituted p-diaminobenzene derivatives | H. LUNDBECK A/S (DK) | 2006-08-17 | — | — | US | claimed |
| CN-1761464-A | Substituted p-diaminobenzene derivatives | LUNDBECK & CO AS H (DK) | 2006-04-19 | — | — | CN | claimed |
| WO-2024054811-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-14 | — | — | WO | disclosed |
| WO-2024054807-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND TDP-43 MODULATORS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-14 | — | — | WO | disclosed |
| WO-2024050389-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND NMDA RECEPTOR ANTAGONISTS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-07 | — | — | WO | disclosed |
| EP-2554162-A1 | Use of KCNQ-Openers for Treating or Reducing the Symptoms of Schizophrenia | H. Lundbeck A/S (DK) | 2013-02-06 | — | — | EP | disclosed |
| US-7906537-B2 | Substituted p-diaminobenzene derivatives | H. LUNDBECK A/S (DK) | 2011-03-15 | — | — | US | disclosed |
| US-20100256145-A1 | USE OF KCNQ POTASSIUM CHANNEL OPENERS FOR REDUCING SYMPTOMS OF OR TREATING DISORDERS OR CONDITIONS WHEREIN THE DOPAMINERGIC SYSTEM IS DISRUPTED | H. LUNDBECK A/S (DK) | 2010-10-07 | — | — | US | disclosed |
| CN-101790374-A | Use of kncq potassium channel openers for reducing symptoms of or treating disorders or conditions wherein the dopaminergic system is disrupted | LUNDBECK & CO AS H | 2010-07-28 | — | — | CN | disclosed |
| EP-2185149-A1 | USE OF KNCQ POTASSIUM CHANNEL OPENERS FOR REDUCING SYMPTOMS OF OR TREATING DISORDERS OR CONDITIONS WHEREIN THE DOPAMINERGIC SYSTEM IS DISRUPTED | H. Lundbeck A/S (DK) | 2010-05-19 | — | — | EP | disclosed |
| US-20090118285-A1 | USE OF KCNQ-OPENERS FOR TREATING OR REDUCING THE SYMPTOMS OF SCHIZOPHRENIA | H. LUNDBECK A/S (DK) | 2009-05-07 | — | — | US | disclosed |
| WO-2009015667-A1 | USE OF KNCQ POTASSIUM CHANNEL OPENERS FOR REDUCING SYMPTOMS OF OR TREATING DISORDERS OR CONDITIONS WHEREIN THE DOPAMINERGIC SYSTEM IS DISRUPTED | H. LUNDBECK A/S (DK) | 2009-02-05 | — | — | WO | disclosed |
| US-20060183791-A1 | Substituted p-diaminobenzene derivatives | H. LUNDBECK A/S (DK) | 2006-08-17 | — | — | US | disclosed |
| CN-1761464-A | Substituted p-diaminobenzene derivatives | LUNDBECK & CO AS H (DK) | 2006-04-19 | — | — | CN | disclosed |
| EP-1613303-A1 | SUBSTITUTED P-DIAMINOBENZENE DERIVATIVES | H. Lundbeck A/S (DK) | 2006-01-11 | — | — | EP | disclosed |
| WO-2004082677-A1 | SUBSTITUTED P-DIAMINOBENZENE DERIVATIVES | H. LUNDBECK A/S (DK) | 2004-09-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060183791-A1 | Substituted p-diaminobenzene derivatives | ABCB1, UGT2B7, CYP2D6 | RAB9A 3710/4885KCNQ3 3629/4885KCNQ2 3655/4885 |
| US-20090118285-A1 | USE OF KCNQ-OPENERS FOR TREATING OR REDUCING THE SYMPTOMS OF SCHIZOPHRENIA | KCNQ4, KCNQ5, KCNQ1 | RAB9A 2336/4885KCNQ3 4/4885KCNQ2 5/4885 |
| US-20100256145-A1 | USE OF KCNQ POTASSIUM CHANNEL OPENERS FOR REDUCING SYMPTOMS OF OR TREATING DISORDERS OR CONDITIONS WHEREIN THE DOPAMINERGIC SYSTEM IS DISRUPTED | KCNQ2, KCNQ4, KCNQ1 | RAB9A 1088/4885KCNQ3 4/4885KCNQ2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.